Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Infinityon Apr 08, 2022 11:24am
162 Views
Post# 34587942

RE:RE:RE:RE:The Data

RE:RE:RE:RE:The DataEnrique, That is a fairly accurate statement. Did not realise that the Data included 5 patients who were removed from the study, this completely makes any statistical conclusion skewed. The only way to draw meaningful conclusions would be to increase the sample size. We need more Patients in the study. One way to enroll more patients is to offer PDT as an option even before trying BCG. Considering the side effects are minimal and manageable, this could potentialy Fast Track the Clinical study. Getting FDA and Health Canada to go along with this requires lot of Input and Guidance from the Medical Advisory Board.... If you are looking purely from the point of benefits to the Patient, this is a very viable alternative.
<< Previous
Bullboard Posts
Next >>